94749-08-3O=C(O)c1ccc2ccccc2c1O.OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1OXTZNCVSCVHTPAI-UHFFFAOYSA-NSalmeterol xinafoate is a naphthoic acid.
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
化学的特性White to Off-White Solid
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
This chemical does not meet GHS hazard criteria for 72.2% (52 of 72) of all reports.
Danger
H318 (15.3%): Causes serious eye damage [Danger Serious eye damage/eye irritation]
P203, P264+P265, P273, P280, P305+P351+P338, P305+P354+P338, P317, P318, P337+P317, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 72 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
SALMETEROL XINAFOATE
beta2-Adrenergic Agonist [EPC]; Adrenergic beta2-Agonists [MoA]
Agents that cause an increase in the expansion of a bronchus or bronchial tubes.
Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS.
説明Salmeterol hydroxynaphthoate is a new long-acting β2-selective adrenoceptor agonist introduced as a bronchodilator for the treatment of reversible airway obstruction in asthma and chronic bronchitis. It has bronchodilatory activity as intense and four times longerlasting than equivalent doses of salbutamol. Salmeterol hydroxynaphthoate is reported to be the first bronchodilator with significant anti-inflammatory activity and hence could complement prophylactic corticosteroid therapy.
使用A -Adrenergic agonist. Structural analog of albuterol
現在のフィルター条件では反応記録がありません。
読み込み中…
94749-08-3DTXSID1045798CHEMBL1082607CHEBI:9012